States Take Unusual Actions To Control On-Label Drug Supply Amidst COVID-19 Shortages
Sixteen US states have issued executive orders or other mandatory directives to preserve hydroxychloroquine and chloroquine for non-COVID-19 patients, while 26 states have issued similar voluntary guidance. The federal government is reserving some of the strategic national stockpile supply of the drugs for non-COVID-19, as private players in the supply chain also join in the efforts to balance on-label use with COVID-related demand.
You may also be interested in...
FDA Commissioner Hahn says industry needs to work with the agency to establish a link to more detailed supply chain information.
Regulators whipsawed by COVID-19-related drug shortages are seeking better ways to forecast demand.
Coronavirus Notebook: US FDA Cuts Hotline Hours, Regulatory Relief May Be Permanent, Trump's Hydroxychloroquine Prescription
Dispatches from a world turned upside down include approval of more hydroxychloroquine ANDAs, a window into what post-pandemic regs at the US FDA might look like, and some bad news for night shift works who need coronavirus advice from the agency.